Aerovate Therapeutics Files 2024 10-K
Ticker: JBIO · Form: 10-K · Filed: Mar 27, 2025 · CIK: 1798749
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals
TL;DR
Aerovate Therapeutics filed its 2024 10-K, detailing financials for the year ending Dec 31, 2024.
AI Summary
Aerovate Therapeutics, Inc. filed its 2024 10-K on March 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, incorporated in Delaware, operates in the pharmaceutical preparations sector and is headquartered in Waltham, MA. Key financial data such as common stock, retained earnings, and additional paid-in capital for the years 2022, 2023, and 2024 are detailed within the filing.
Why It Matters
This filing provides investors with a comprehensive overview of Aerovate Therapeutics' financial health and operational status for the fiscal year 2024, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Aerovate Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 28985019 — Total Assets (Reported for 2024)
- 27762703 — Total Liabilities (Reported for 2024)
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-27 (date) — Filing date
- Waltham, MA (location) — Company headquarters
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
FAQ
What were Aerovate Therapeutics' total assets and liabilities as of December 31, 2024?
As of December 31, 2024, Aerovate Therapeutics reported total assets of $28,985,019 and total liabilities of $27,762,703.
What is Aerovate Therapeutics' Standard Industrial Classification (SIC) code?
Aerovate Therapeutics' SIC code is 2834, which corresponds to Pharmaceutical Preparations.
When did Aerovate Therapeutics file its 10-K for the fiscal year ending December 31, 2024?
Aerovate Therapeutics filed its 10-K for the fiscal year ending December 31, 2024, on March 27, 2025.
Where is Aerovate Therapeutics, Inc. headquartered?
Aerovate Therapeutics, Inc. is headquartered in Waltham, MA.
What are the key financial statement components reported for Aerovate Therapeutics in this filing?
The filing details components such as Common Stock, Retained Earnings, Additional Paid-In Capital, and Accumulated Other Comprehensive Income for the fiscal years 2022, 2023, and 2024.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 27, 2025 regarding Aerovate Therapeutics, Inc. (JBIO).